Jim Simons Candel Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $63.6 Billion
- Q1 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 56,905 shares of CADL stock, worth $321,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,905
Previous 18,675
204.71%
Holding current value
$321,513
Previous $27,000
233.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CADL
# of Institutions
22Shares Held
3.86MCall Options Held
0Put Options Held
0-
Northpond Ventures, LLC1.94MShares$10.9 Million8.58% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA812KShares$4.59 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA541KShares$3.06 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$823,2380.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX82.6KShares$466,6610.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $163M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...